Insys Therapeutics (INSY) Approves $50M Common Stock Buyback
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Insys Therapeutics Announces Stock Repurchase Program
November 5, 2015 6:52 AM ESTPHOENIX, Nov. 05, 2015 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (Nasdaq: INSY) (Insys or the Company) today announced that its Board of Directors has approved the repurchase of up to $50 million of the Company's common stock.
"The Board of Directors and management team believe that shares of Insys stock are an attractive investment opportunity, and we are pleased that Insys strong balance sheet and cash flow enable us to return value to shareholders through a stock repurchase program, said Dr. John Kapoor, Chairman, President and Chief Executive Officer. At the same time, we are continuing to... More
Insys Therapeutics Announces Stock Repurchase Program
November 5, 2015 6:52 AM ESTPHOENIX, Nov. 05, 2015 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (Nasdaq: INSY) (Insys or the Company) today announced that its Board of Directors has approved the repurchase of up to $50 million of the Company's common stock.
"The Board of Directors and management team believe that shares of Insys stock are an attractive investment opportunity, and we are pleased that Insys strong balance sheet and cash flow enable us to return value to shareholders through a stock repurchase program, said Dr. John Kapoor, Chairman, President and Chief Executive Officer. At the same time, we are continuing to... More
Insys Therapeutics Announces Senior Management Changes and Appointments
November 5, 2015 6:51 AM ESTMichael Babich Departs as Insys President and CEO
Dr. John N. Kapoor Appointed President and CEO
Daniel Brennan Appointed Executive Vice President and Chief Operating Officer
PHOENIX, Nov. 05, 2015 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ: INSY) ("Insys" or "the Company") today announced that Michael L. Babich has stepped down as President and Chief Executive Officer of Insys. The Board of Directors has appointed Dr. John N. Kapoor as President and Chief Executive Officer effective November 4, 2015. Dr. Kapoor will... More
